## BAX: Baxter International Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.5% below STRENGTH zone (4.0-10.0%); PEG 33.66 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($17.78)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 2, Bearish: 0)

**1. Here’s What Pressured Baxter International (BAX) in Q3**
- Source: Insider Monkey | 20251210T084100 | Neutral | Relevance: 99%
-  Pzena Investment Management's "Pzena Focused Value Strategy" commented on Baxter International (BAX) in its Q3 2025 letter, noting disappointing earnings due to a product recall and slow IV fluid demand recovery. Despite these pressures, the strategy added to its position, viewing the issues as transitory and the stock price reaction disproportionate to the earnings pressure. Baxter International's shares saw a one-month return of -2.89% and a 41.42% loss over the last 52 weeks, closing at $18.48 per share on December 9, 2025.

**2. Pomerantz LLP Posts Reminder: Legal Action Filed Against Baxter International, Inc. – BAX**
- Source: WTRF | 20251211T120754 | Neutral | Relevance: 99%
-  Pomerantz LLP announced a class action lawsuit against Baxter International, Inc. (NYSE: BAX) concerning alleged securities fraud. The lawsuit follows Baxter's decision to pause shipments of its Novum LVP medical device, which led to a significant drop in the company's stock price. Investors who purchased Baxter securities during the Class Period have until December 15, 2025, to seek appointment as Lead Plaintiff.

**3. Baxter Presents Real-World Data at American Society of Health System Pharmacists Meeting Demonstrating Smart Infusion Pump Electronic Medical Record (EMR) Integration May Improve Patient Safety and Nursing Bedside Productivity**
- Source: PharmiWeb.com | 20251211T163608 | Bullish | Relevance: 99%
-  Baxter International Inc. announced real-world data showing that smart infusion pump integration with hospital EMRs positively impacts patient safety, clinician productivity, and programming compliance. Data from over one million infusions using Baxter's Spectrum IQ pumps at The University of Texas Medical Branch indicated a significant reduction in patient safety alerts and decreased time spent on programming and alert resolution. These findings highlight the potential of connected infusion therapy to enhance patient safety and alleviate clinician workload.

**4. Pomerantz LLP Notifies Shareholders of Class Action Lawsuit Against Baxter International, Inc. – BAX**
- Source: WATE 6 On Your Side | 20251209T120754 | Neutral | Relevance: 99%
-  Pomerantz LLP has announced a class action lawsuit against Baxter International, Inc. (NYSE:BAX) concerning alleged securities fraud. The lawsuit stems from Baxter's voluntary and temporary pause of shipments for its Novum LVP medical device, which caused a significant drop in its stock price. Investors who purchased Baxter securities during the Class Period have until December 15, 2025, to seek appointment as Lead Plaintiff.

**5. Pomerantz LLP Notifies Shareholders of Lawsuit Filed Against Baxter International, Inc. – BAX**
- Source: KFOR.com | 20251210T120742 | Neutral | Relevance: 99%
-  Pomerantz LLP has filed a class action lawsuit against Baxter International, Inc. (NYSE: BAX) on behalf of shareholders, alleging securities fraud or other unlawful business practices. The lawsuit stems from Baxter's voluntary and temporary pause on shipments of its Novum LVP medical device, which caused a significant drop in the company's stock price. Shareholders who purchased Baxter securities during the Class Period have until December 15, 2025, to seek appointment as Lead Plaintiff.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $15 | $19 | -21% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.16M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 65.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 15.1% (+14.9%)
- Vanguard Group Inc: 12.2% (+0.5%)
- Dodge & Cox Inc.: 11.2% (+10.1%)
- Pzena Investment Man: 11.2% (+45.9%)
- State Street Corpora: 4.3% (+0.3%)

### Key Risks

1. Valuation stretched: PEG 33.7x requires aggressive growth execution.
2. Elevated short interest (9.7%): bears positioning against stock.
3. Long-term trend broken: trading 29.1% below SMA200.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +1.8% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 33.66 signals overvaluation risk, limited margin of safety. Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.7B |
| Beta | 0.61 |
| 52W Range | $17.40 - $37.74 |
| Short Interest | 9.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 33.66 |
| Forward P/E | 8.2 |
| Current P/E | 8.0 |
| YoY Growth | -2.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -1.4% to 0.5% (+1.8% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.5pp (needs >4.0% for momentum thesis). MRS_5 at 2.7% confirms short-term momentum alignment. Below SMA200 (0.71x), long-term trend not supportive. RSI neutral at 50.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.45% (CS: 48) | Neutral |
| RSI_14 | 49.6 | Neutral |
| MACD Histogram | 0.15 | Bullish |
| vs SMA20 | 1.026x | Above |
| vs SMA50 | 0.937x | Below |
| vs SMA200 | 0.709x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $18.90
- **Stop Loss:** $17.78 (5.9% risk)
- **Target:** $20.02 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 1232
- **Position Value:** $23,284.80
- **Portfolio %:** 23.28%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-19 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.60 | $0.69 | +15.4% |
| 2025Q2 | $0.61 | $0.54 | -11.5% |
| 2025Q1 | $0.48 | $0.55 | +13.8% |
| 2024Q4 | $0.53 | $0.58 | +9.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*